Skip to main content

Retisert FDA Approval History

FDA Approved: Yes (First approved April 8, 2005)
Brand name: Retisert
Generic name: fluocinolone acetonide
Dosage form: Intravitreal Implant
Company: Bausch & Lomb
Treatment for: Uveitis

Retisert (fluocinolone acetonide) intravitreal implant is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Development timeline for Retisert

Apr  8, 2005Approval Retisert Bausch & Lomb - Treatment for Chronic Non-Infectious Uveitis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.